Neu-Sensamide metoclopramide: Discontinued Phase III trials development

OXGN said it will focus on its three small molecules. The company is conducting Phase I trials of Combretastatin A-4 prodrug vascular targeting agent to treat tumors, Phase I/II trials with Decloprami...